ArticlePloS one2020

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.

Szu-Chun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.